|
|
Article: Study Demonstrates Utility of Telomerase Promoter.
- Article from:
- Gene Therapy Weekly
- Article date:
- April 19, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 APR 19 - (NewsRx.com & NewsRx.net) --
Geron Corp. (GERN) announced the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells.
The research, described in the April 4, 2001, issue of Gene Therapy, shows that the cloned promoter of the human telomerase reverse transcriptase (hTERT) gene can drive the selective expression of therapeutic genes in cancer cells in vitro and in vivo, while remaining inactive in normal somatic cells and tissues.
The research takes advantage of the fact that hTERT is expressed in essentially all human cancers, in ...